Foxp3-modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats
© Qi et al. 2015
Received: 10 February 2015
Accepted: 13 August 2015
Published: 21 August 2015
The transcription factor forkhead box P3 (Foxp3) is a master regulatory gene necessary for the development and function of CD4+CD25+ regulatory T cells (Tregs). Mesenchymal stem cells (MSC) have recently emerged as promising candidates for cell-based immunosuppression/tolerance induction protocols. Thus, we hypothesized that MSC-based Foxp3 gene therapy would improve immunosuppressive capacity of MSC and induce donor-specific allograft tolerance in rat’s liver allograft model.
The present study utilized a lentivirus vector to overexpress the therapeutic gene Foxp3 on MSC. In vivo, Injections of 2 × 106 MSC, FUGW-MSC or Foxp3-MSC into the portal vein were carried out immediately after liver transplantation.
Successful gene transfer of Foxp3 in MSC was achieved by lentivirus carrying Foxp3 and Foxp3-MSC engraftment in liver allograft was confirmed by fluorescence microscopy. Foxp3-MSC treatment significantly inhibited the proliferation of allogeneic ACI CD4+ T cells to splenocytes (SC) from the same donor strain or third-party BN rat compared with MSC. Foxp3-MSC suppressive effect on the proliferation of CD4+ T cells is contact dependent and associated with Programmed death ligand 1(PD-L1) upregulation in MSC. Co-culture of CD4+ T cells with Foxp3-MSC results in a shift towards a Tregs phenotype. More importantly, Foxp3-MSC monotherapy achieved donor-specific liver allograft tolerance and generated a state of CD4+CD25+Foxp3+ Tregs-dependent tolerance.
Foxp3-engineered MSC therapy seems to be a promising and attractive cell therapy approach for inducing immunosuppression or transplant tolerance.
Transplant tolerance describes immunological unresponsiveness to donor alloantigens without the need for long-term administration of immunosuppressive drugs, while immune responsiveness to pathogens and malignant cells is maintained . It is a major goal in transplantation. Gene therapy, in which malfunctioning cells are repaired by mending their DNA, offers an elegant solution to induce transplant tolerance. However, many potential problems associated with this modality of treatment have been encountered, including difficulty in regulating transgene expression, safety concerns about malignancy, infection, and inflammation [2, 3]. Determining a safe and efficient means of gene delivery and finding an optimal gene for such are believed to be keys to solving these problems.
Mesenchymal stem cells (MSC) are considered as adult stem cells with the greatest therapeutic potential because of their characteristics, which include plasticity, migratory ability, paracrine activity, and immunosuppressive activity [4, 5]. This potential may be amplified by transforming them with genes that will improve their therapeutic ability [4, 6]. MSC have recently emerged as promising candidates for cell-based immunotherapy [7–9]. MSC can inhibit immune responses and influence all components of the immune system as shown for T-, B-, natural killer-, monocytic and dendritic cells in vitro and in vivo [5, 10]. With regard to solid organ transplantation, MSC were reported to prolong skin allograft survival in baboons , heart [7, 8], liver , renal  and islet  graft survival in rodent transplantation models. In addition, MSC were already successfully employed in several clinical trials [14, 15] most notably to ameliorate steroid-resistant graft-versus-host disease in a phase II study . Importantly, the immunoregulatory effects of MSC are associated with the expansion of Foxp3+ regulatory T cells (Tregs) [7–9, 12] and in some cases to generate a state of Foxp3+ Tregs-dependent tolerance [7, 8, 12, 15]. All of these studies elegantly show the importance of Foxp3+ Tregs in MSC induced tolerance using Foxp3+ Tregs depletion or adoptive transfer of Foxp3+ Tregs studies [7, 8, 12, 15].
Tregs are a CD4+ T cell population essential for maintaining self-tolerance and immune homeostasis [17, 18]. The role for Foxp3+ Tregs in allograft tolerance has received strong support from observations, including enhanced graft survival by adoptive transfer of Tregs populations [19, 20], the presence of small numbers of Tregs within the graft [21, 22] and peripheral induction of Foxp3+ Tregs following a tolerogenic protocol [23, 24]. A recent study provided definite proof that Foxp3+ Tregs are required not only to induce, but also to maintain the tolerant state . Therefore, therapeutic strategies to induce and expand Foxp3+ Tregs in vivo may provide an attractive approach to guide the immune reconstitution towards tolerance.
The transcription factor forkhead box P3 (Foxp3), which encodes a forkhead/winged helix transcription factor known as scurfin, is a known master regulatory gene for the development and function of CD4+CD25+ Tregs that plays a vital role in both natural and induced Tregs differentiation from noncommitted precursors [18, 26]. Previous studies have shown that Foxp3 is expressed specifically by Foxp3+ Tregs in the thymus and periphery of normal mice and humans, and its expression cannot be induced in naive T cells simply by activation [27, 28]. The retroviral transfer of Foxp3 converts naive T cells into a Tregs phenotype and function . Moreover, recent studies have reported a large number of key target genes which were regulated directly by Foxp3 during T stimulation, such as CD25, programmed cell death-1(PD-1)/programmed death ligand 1(PD-L1), CD28 and neuropilin-1 (Nrp-1), these target genes are the key modulators of immunosuppression [29, 30]. Based on these data, we utilized the characteristics of Foxp3 and MSC, then overexpressed Foxp3 in MSC through lentivirus carrying human Foxp3. We hypothesized that overexpression of Foxp3 in MSC could improve immunosuppressive capacity of MSC and induce donor-specific allograft tolerance in rat’s liver allograft model.
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health). The protocol was approved by the Animal Ethics Committee of Central South University. All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize animal suffering.
Isolation, culture, and characterization of MSC
Isolation and primary culture of MSC were performed according to previously reported method . Isolated MSC were routinely characterized inhouse by flow cytometry for their cell surface markers, and differentiation of MSC into adipocytes, chondrocytes and osteoblasts in vitro was performed as previously described . Passage 6–8 MSC were used for all experiments described. LEW MSC derived from the bone marrow were positive for MHC class I (RT1Al), Thy1 (CD90) and CD73, showed a weak expression of CD80 but lacked the expression of MHC class II, CD4, CD25, CD45, and CD49b as shown by flow cytometry. The resultant MSC had a spindle-shaped fibroblastic morphology and maintained their multilineage differentiation potential by maintaining their ability to differentiate into osterogenic, chondrogenic and adipogenic lineages when cultured in various specific differentiation media.
Splenocyte (SC) suspensions were obtained by passing the mouse spleen through a 70-μm cell stainless steel strainer, and erythrocytes were depleted by hypotonic lysis. T cell-depleted SC (act as APC) were enriched from pooled spleens by positive selection via magnetic-activated cell sorting (MACS) using a Pan T Cell Isolation Kit (Miltenyi Biotec). CD4+ T cells were enriched from the same pool by negative selection via MACS using a CD4+ T Cell Isolation Kit (Miltenyi Biotec). CD4+CD25− T cells were sorted by antibody cell sorting on an FACS Vantage SE with a FACS Diva Cell Sorter (BD Bioscience) to >99 % purity.
Antibodies and FACS analysis
The following monoclonal antibodies (mAbs) used: anti-rat-Nrp-PE, anti-mouse-PD-L1-PE (eBioscience, San Diego, CA), anti-mouse/rat CD28-PE (Santa Cruz, CA), anti-rat CD4-FITC, anti-rat CD25-PE, anti-rat Foxp3-PE-cyanine 5 (eBioscience, San Diego, CA, USA). After membrane and intracellular staining, cells were analyzed on FACS CantoII using the BD FACSDiva v8.0 software.
Production of lentivirus
Lentivector (FUGW) and packaging (psPAX2) and envelope plasmids (pMD2.G) were obtained from Addgene. The cDNA encoding full-length human Foxp3 (NM_014009.3) was amplified by RT-PCR from the cDNA of adult peripheral cells using specific primers, and digested with restriction enzymes subcloned to lentiviral vector backbone plasmid FUGW. To produce the recombinant lentivirus carrying Foxp3 (Foxp3) and control GFP (FUGW), the recombinant plasmid and vector were co-transfected with packaging and enveloping plasmids into 293FT cells by calcium phosphate transfection. The culture supernatant containing the virus was collected and centrifuged at 15,000 rpm/min for 10 min to remove debris, and then transferred into a 36-mL ultracentrifuge tube for ultracentrifugation at 25,000 rpm/min for 3 h. The pellet containing lentivirus was resuspended. MSC were infected with the appropriate lentivirus where gene transfer efficiency reached at least 80 %.
Animals and experimental groups
Experimental groups and liver allograft survival in ACI recipients
Graft survival (days)
11, 13 × 2, 14, 15, 16
16, 18, 20, 21 × 3, 24, 26
63, >100 × 7
18 × 2, 20 × 2, 21, 23
Lewis Foxp3-MSC + α-CD25
12, 14 × 3, 16, 18
Lewis Foxp3-MSC + IgG
>100 × 6
17, 19, 25, 26, 30, 35
31, 35, 41, 73, >100 × 2
Flow cytometry analysis
Cells were analyzed on a flow cytometer (BD Bioscience) according to a previously reported method . For intracellular staining, cells were fixed and permeabilized with Cytofix/Cytoperm (BD PharMingen). The following mAbs were included: anti-rat CD25-PE, anti-rat CD4-FITC, and anti-rat Foxp3-PE-cyanine 5 (eBioscience, San Diego, CA, USA). As to the Foxp3 antibody, an isotype-matched control was used to determine the background. Tregs were identified as CD4+CD25+Foxp3+ triple-positive cells and were expressed as percentages in SC.
MLR and proliferation studies
MLR and proliferation studies were performed as previously described . CD4+ T cells were used as responders (0.5 × 106 cells) in the MLR. We used 4000-rad irradiated SC (0.5 × 106 cells) as stimulators. Cocultures also contained MSC from Lewis rats at ratios of 1:1 and 1:100 in RPMI medium (Gibco Invitrogen, Karlsruhe, Germany) supplemented with 10 % FBS with 800 U/mL rat interleukin-2 (IL-2; BD Bioscience, Bedford, MA, USA). Transwell inserts were used in some wells (0.4-μm pore size; BDFalcon, San Jose, CA, USA). CD4+ T cells were cultured in the well beneath the insert. Cell proliferation was determined by pulsing the cells with [3H]thymidine during the last 14–16 h of culture and measuring the radioactivity incorporated by liquid scintillation counting. Proliferative response was expressed as △cpm.
Long-term ACI liver allograft recipients received full-thickness skin grafts (1 × 1 cm2) from LEW donor and BN rat strains on postoperative day (POD) 100 and were monitored daily (n = 3). Rejection was defined as scar formation or epidermis sloughing or both.
Histology and liver function post-orthotopic liver transplantation
Samples of liver tissue for histopathology were fixed by immersion in 4 % buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin-eosin. The histological findings of hematoxylin-eosin staining were graded according to the Banff scheme and rejection activity index (RAI) was calculated from the three individual scores [35, 36]. For the evaluation of the engraftment of GFP-MSC in the liver, tissues from GFP-labeled, MSC infused Lewis donor were rapidly frozen, sectioned on a cryostat (6 μm), fixed with acetone, and analyzed directly by fluorescence microscopy. For each tissue, three nonconsecutive sections were analyzed and GFP+ cells in each section were counted. Immunohistochemistry (IHC) was performed with anti-rat Foxp3 mAbs (1:100) according to the procedures described in the BioLegend protocol. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) were measured with an autobiochemical analyzer (CX7; Beckman Coulter, Inc., Brea, CA, USA).
CD25+ cell depletion
CD25+ cells Deplation in vivo was performed as previously described . Briefly, mice received 15 mg/kg of rat anti-mouse CD25 mAb (clone PC-61, BioXcell) on days −2, 0, 2 after transplantation, CD25+ cell depletion was confirmed on POD7 by staining splenocytes. Rat IgG1 injections at the same time point to reciprocal recipients served as isotype-matched controls.
Allograft survival among experimental groups was compared using log-rank (Mantel-Cox) testing. Statistical analysis for multiplicity was conducted using a one-way ANOVA or the Student t-test. Statistical Package for the Social Sciences for Windows (Version 14.0; SPSS Inc.) software was used for all statistical analyses, and p < 0.05 was considered statistically significant.
Successful gene transfer of foxp3 in MSC and Foxp3-MSC engraftment in liver allograft
We next evaluated Foxp3-MSC engraftment in liver grafts by fluorescence microscopy. As demonstrated in Fig. 1c, we detected substantial numbers of GFP-Foxp3-MSC (approximately 10–20 cells per section) liver graft of the recipients on POD7 after intraportal injection of allogeneic GFP-Foxp3-MSC. These finding suggests that Foxp3-MSC successful locates in the liver allograft.
Foxp3 transduction improved the immunosuppressive capacity of MSC and Foxp3-MSC mediated immunomodulation involves cell–cell contact mechanisms
To investigate the effects of Foxp3-engineered MSC on immunosuppressive activity, MLR and proliferation studies were performed. LEW MSC or Foxp3-MSC (MSC/Foxp3-MSC: CD4+ T cells = 1:10) significantly lowered the proliferative response of allogeneic ACI CD4+ T cells elicited by SC from the same MSC donor strain compared with PBS control group (Fig. 2a). LEW MSC or Foxp3-MSC at the same concentration also significantly reduced the proliferation of allogeneic ACI CD4+ T cells to third-party SC from BN rat (Fig. 2a). Furthermore, Foxp3-MSC treatment was significantly lower than the proliferation of allogeneic ACI CD4+ T cells induced by SC from the same donor strain or third-party BN rat compared with MSC (Fig. 2a). To further test the effects of Foxp3-engineered MSC on immunosuppressive activity. ACI CD4+ T cells were cultured in MLR with allogeneic LEW SC in the presence of graded doses of LEW MSC or Foxp3-MSC. Both MSC and Foxp3-MSC were able to suppress the proliferation of allogeneic CD4+ T cells to alloantigens in a dose-dependent manner and Foxp3-MSC showed higher immunosuppressive power when compared with MSC (Fig. 2b). Therefore, both Foxp3-MSC and MSC are not immunogenic and donor specific, Foxp3-MSC share the similar immunological properties with MSC and Foxp3 transduction significantly improved the immunosuppressive capacity of MSC.
MSC-mediated immunomodulation involves both cell contact–dependent and cell contact–independent mechanisms mediated through the release of soluble factors. To determine the role of cell contact, trans-well experiments were performed, in which direct contact between T cells and allogeneic Foxp3-MSC was prevented, Fig. 2a shows that when cell–cell contact is prevented, similar to MSC, the suppression effect of Foxp3-MSC on the proliferation of ACI CD4+ T cells is significantly alleviated (p < 0.05 vs Foxp3-MSC). Therefore, the cell–cell contact is required to immunosuppresion activity of Foxp3-MSC.
We further investigate the phenotype of MSC altered by Foxp3 transduction. Foxp3-MSC and FUGW-MSC were isolated using a FACS and CD25, CD28, Nrp-1, and PD-L1 regulated by transcription factors Foxp3 [30, 37] were detected by FCM. MSC overexpressing Foxp3 increased the expression of cell surface molecule Nrp-1 and costimulatory molecule PD-L1 compared with FUGW-MSC (Fig. 2c); however, no difference between the two groups in the expression of cell surface molecule CD25 and costimulatory molecule CD28 was found (Fig. 2c). To study the role of the Nrp-1 and PD-L1 in mediating suppression of CD4+ T cell proliferation by LEW Foxp3-MSC, blocking experiments were performed using 10 μg/ml of neutralizing antibodies against PD-L1 or Nrp-1. Foxp3-MSC treated with anti-PD-L1 significantly increased the proliferation of allogeneic ACI CD4+ T cells elicited by SCs from LEW compared with Foxp3-MSC with IgG, while the presence of 10 μg/ml of anti-PD-L1 antibody did not produce significant effect on the FUGW-MSC mediated inhibition of cell proliferation (Fig. 2d). Thus, the increased expression of PD-L1 in Foxp3-engineered MSC may be associated with its immunosuppressive capacity. On the other hand, the blockade of Nrp-1 did not produce significant effect on the FUGW-MSC or Foxp3-MSC mediated inhibition of CD4+ T cells proliferation (Fig. 2e).
Foxp3 transduction induced the expansion of Foxp3+ Tregs in vitro
To determine whether or not the immunoregulatory actions of Foxp3-MSC were associated with the expansion of Tregs, CD4+ T cells were cocultured with MSC, Foxp3-MSC, or FUGW-MSC for 7d in the presence of APC and anti-CD3 mAb, and their FCM results were analyzed. Figure 2f, g shows that the MSC markedly increased the percentage of CD4+CD25+Foxp3+ T-cell population after 7 days of cocultures with CD4+ T cells, Furthermore, the percentage of CD4+CD25+Foxp3+ Tregs in the Foxp3-MSC group was significant higher than that in the MSC group.
Foxp3-MSC monotherapy achieves donor-specific liver allograft tolerance
Next, we examined the pathology and function of liver allografts. As shown in Fig. 3c, severe acute rejection was present in the untreated groups at day 7 postoperatively; moderate acute rejection with milder vacuolation of hepatic cells and less inflammatory cell infiltration were observed in rat treated with MSC or FUGW-MSC compared to untreated group. However, Foxp3-MSC treatment achieved almost normal histology on POD 7. At the same time, RAI score of Foxp3-MSC group was markly lower than that in untreated, MSC or FUGW-MSC control group (Fig. 3d). The serum concentrations of liver enzymes (ALT and AST) and TBIL were significantly decreased after Foxp3-MSC treatment compared with those after treatment with untreated, MSC or negative control lentivirus (Fig. 3e, f).
To study whether the long-term graft acceptance was associated with donor-specific tolerance, Full-thickness skin transplantation was also performed, skin grafts from either LEW donor or BN third-party rat were transplanted to long-term surviving ACI recipients on POD 100, BN third-party skin grafts were rejected within 14 days, while LEW donor skin grafts were survived over 100 days (data not shown). A histological examination of skin grafts were completed on POD 7 after skin transplantation, intense infiltration of inflammatory cells was observed in the epidermis and dermis of the BN third-party skin grafts (Fig. 3g) but not in LEW donor skin grafts, indicating that donor-specific tolerance was achieved in LEW Foxp3-MSC treated liver allograft recipients.
Foxp3-MSC increase CD4+CD25+Foxp3+ Tregs frequencies and generate a state of CD4+CD25+Foxp3+ Tregs-dependent tolerance
To understand the immunological role of CD4+CD25+Foxp3+ Tregs behind Foxp3-MSC mediated long-term graft acceptance, CD25+ T cells were depleted by in vivo administration of an α-CD25 monoclonal antibody (mAb) on days −2, 0, 2 after transplantation, and CD4+CD25+Foxp3+ T cells frequencies were confirmed less than 0.9 % of the mononuclear cell population on POD7. As shown in Table 1 and Fig. 3b, although having received Foxp3-MSC treatment, liver grafts were rejected in 20 days after CD25+ T cells depletion. In contrast, Foxp3-MSC recipients received isotype control IgG maintained long-term liver graft survival. These data further indicating a critical role for Foxp3+ Tregs in Foxp3-MSC inducing tolerance.
MSC have recently emerged as promising candidates for cell-based immunosuppression/tolerance and can be easily obtained and propagated in culture [7–9]. However, treatment with MSC alone only prolonged allograft survival but could not induce allograft tolerance in rodent transplantation models [8, 9, 11, 13, 38, 39]. MSC also only be applied as a complement to standard immunosuppressive therapy in a clinical setting [14, 15]. Previous studies have been performed to show that gene modification of MSC, including the incorporation of exogenous genes such as IL-10 , hepatocyte growth factor , IL-7  successfully improve MSC therapeutic ability. In the present study, we intended to enhance the tolerogenic effect of MSC by overexpressing gene Foxp3. Our results show that Foxp3-MSC is not donor specific/immunogenic, Foxp3 transduction significantly improve the immunosuppressive capacity of MSC, Foxp3-MSC suppressive effect on the proliferation of CD4+ T cells is contact dependent and associated with PD-L1 upregulation. More importantly, Foxp3-MSC monotherapy achieves donor-specific liver allograft tolerance, the tolerogenic potential of Foxp3-MSC is associated with the expansion of CD4+CD25+Foxp3+ Tregs.
Foxp3 is essential for specifying the Foxp3+ Treg cell lineage during development, and continued expression of Foxp3 in mature Treg cells is necessary for suppressive function . Deletion of Foxp3 in fully differentiated mature Treg cells results in the deregulation of its target genes and the loss of suppression function . Previous studies have identified Foxp3 target genes and reported a large number of Foxp3-bound genes that are up- or down-regulated in Foxp3+ T cells, suggesting that Foxp3 acts as both a transcriptional activator and a repressor. Furthermore, Foxp3 probably sets up a transcription factor network controlling the overall functional program of Tregs [29, 30]. The present study utilized a lentivirus vector to modify MSC to overexpress the therapeutic gene Foxp3, the findings suggested that the immunosuppressive effect of rat Foxp3-MSC was dose dependent and not donor specific/immunogenic in vitro. Indeed, Foxp3-MSC/MSC inhibited the proliferative response of both autologous and allogeneic CD4+ T cells to either donor or third-party alloantigens in MLR, which is consistent with most published studies [7–9, 11–13]. Moreover, Foxp3 transduction significantly improved the immunosuppressive capacity of MSC, Further analyses indicated that Foxp3-MSC mediated immunomodulation involved cell–cell contact mechanisms. Using neutralizing antibodies specific for PD-L1, we showed that the mechanisms by which Foxp3-MSC mediated enhanced immunosuppressive capacity was associated with costimulatory molecule PD-L1 of MSC altered by Foxp3 transduction.
Programmed death-1 (PD-1) is a molecule expressed on various cell types, including a subset of thymocytes and activated T and B cells that plays an important role in the negative regulation of immune responses and the maintenance of peripheral tolerance . PD-1 ligand, PD-L1, broadly expressed in different tissues, has been shown to be further induced by exposure to interferon (IFN)-γ on several tumour cell lines and MSC [45, 46]. The exact immune functions of PD-L1 are not fully understood. With respect to immunosuppression mediated by MSC, our findings are consistent with previous study that murine MSC inhibit lymphocyte proliferation by activation of the PD-L1-mediated signaling pathway . The study showed that MSC inhibited the activation and proliferation of murine lymphocytes via engagement of the inhibitory molecule PD-L1 to its cognate receptor on target immune cells, and MSC-mediated inhibition could be blocked by anti-PD-L1 antibody [47, 48]. Recently, it has been shown that IFN-γ acts directly on MSC leading to an up-regulation of PD-L1, and PD-L1 knockdown abolished MSC suppressive properties . In vivo, the combination therapy of MSC with PD-L1 expression and rapamycin induced immune tolerance to cardiac allografts, while the blockade of PD-L1 on MSC with monoclonal antibody abrogated the combination therapy-induced immune tolerance . The PD-1/PD-L1 pathway is essential for costimulatory blockade-induced allograft tolerance, which reflects the roles of the pathway in controlling T effector cell proliferation, as well as the induction of T-cell anergy . However, whereas English and collaborators reported that PD-1 pathway was not essential for MSC mediated immunosuppression . The reasons for these differences are most likely due to the use of different stem cell populations and immune cells. Indeed, the authors used not only MSC with different phenotypes but also heterogeneous population of immune cells such as splenocytes or lymphocytes. Taken together our results demonstrated the cell-to-cell contact depend mechanism of Foxp3-MSC immunosuppression on CD4+ T cells is most likely to involve the up-regulation of PD-L1.
In order to determine how Foxp3-MSC modulated Tregs in our study, we cocultured Foxp3-MSC/MSC with CD4+ T cells in vitro (MLR) to mimic some of the conditions in vivo. Co-culture of CD4+ T cells with Foxp3-MSC results in a shift towards a Tregs phenotype compared with MSC group. MSC are known to express cell adhesion molecules  and several authors have confirmed that direct interaction with target cells is a requirement for their overall immunosuppressive effect [53, 54]. However, there is currently a notable lack of information on the importance of, and mechanisms underlying, the induction of Tregs by MSC via contact-dependent mechanisms . Studies have also shown other factors may be able to substitute for cell-to-cell contact in some situations, as cell-to-cell contact was essential when MSC were co-cultured with purified CD4+ T cells, but this direct interaction was not essential when MSC were exposed to an un-fractionated mononuclear cell population . These findings are consistent with a cell contact-dependent mechanism as suggested by the phenotype of MSC altered by Foxp3 transduction experiments in which Foxp3 transduction led to an up-regulation of PD-L1 on MSC. In the present study, the importance of Tregs in induction of transplant tolerance was also supported by high frequencies of Foxp3+ Tregs in the spleens and liver allografts of tolerant recipients. Antibody-mediated depletion of CD25+ cells abrogated liver allograft tolerance despite administration of Foxp3-MSC, further indicating a critical role for Tregs. These results suggested that the induction and maintenance phases of tolerance after donor-derived Foxp3-MSC infusion in rats are associated with the emergence of functional Tregs.
In this study, Foxp3-MSC/MSC were well detected in the recipient liver allografts after portal vein injection, suggests that Foxp3-MSC/MSC migration and/or proliferation is influenced by tissue injury and/or inflammatory signals. These results are also in line with previous studies indicating that the liver is an immune privileged organ for tolerance induction by donor cell infusion [7, 9, 15]. Foxp3-MSC treatment significantly lowered the proliferation of allogeneic ACI CD4+ T cells to SC from the same donor strain or third-party BN rat. However, in our model third party MSC did not induce graft tolerance, whereas two out of six animals treated with recipient-derived Foxp3-MSC accepted their grafts long-term (Table 1; Fig. 3b). These findings are consistent with previous studies [7, 32] and implicate that MSC cannot be used from arbitrary donors in a clinical transplantation setting. Understanding the mechanism behind MSC mediated tolerance most likely helps to augment the efficiency of recipient-derived MSC, which makes this strategy clinically applicable to cadaveric organ transplantation.
In this study, Foxp3 transduction significantly improved the immunosuppressive activity of MSC, although immunomodulatory mechanisms of Foxp3-MSC remain unclear, Foxp3-MSC suppressive effect on the proliferation of CD4+ T cells is contact dependent and associated with PD-L1 upregulation. Foxp3 transduction induced the expansion of Foxp3+ Tregs and they played an important role in Foxp3-MSC induced liver allograft tolerance. Foxp3-engineered MSC therapy seems to be a promising and attractive cell therapy approach for inducing immunosuppression or transplant tolerance.
carboxyfluorescein diacetate succinimidyl ester
Dulbecco’s modified Eagle’s medium
fetal bovine serum
transcription factor forkhead box P3
Foxp3 modified MSC
FUGW modified MSC
magnetic-activated cell sorting
mixed lymphocyte reaction
mesenchymal stem cells
mean survival time
phosphate buffer solution
programmed cell death-1
programmed death ligand 1
rejection activity index
regulatory T cells
JL: conception and design, provision of study material, carried out parts of the experiments, data analysis and interpretation, manuscript writing, financial support, final approval of manuscript. HQ: conception and design, manuscript writing, final approval of manuscript. GC and YH: carried out parts of the experiments, collection and/or assembly of data, data analysis and interpretation. SZ: quality control. All authors read and approved the final manuscript.
This work was supported by the National Natural Science Foundation of China (Grant No. 81102241) and Specialized Research Fund for the Doctoral Program of Higher Education in China (New Teachers, Grant No. 20110162120016).
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing of interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Long E, Wood KJ. Understanding FOXP3: progress towards achieving transplantation tolerance. Transplantation. 2007;84(4):459–61.View ArticlePubMedGoogle Scholar
- Lai Y, Drobinskaya I, Kolossov E, Chen C, Linn T. Genetic modification of cells for transplantation. Adv Drug Deliv Rev. 2008;60(2):146–59.View ArticlePubMedGoogle Scholar
- Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 2006;58(4):467–86.View ArticlePubMedGoogle Scholar
- Dalberto TP, Nardi NB, Camassola M. Mesenchymal stem cells as a platform for gene therapy protocols. Sci Prog. 2010;93(Pt 2):129–40.View ArticlePubMedGoogle Scholar
- Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36(10):2566–73.View ArticlePubMedGoogle Scholar
- Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun. 2008;30(3):121–7.View ArticlePubMedGoogle Scholar
- Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181(6):3933–46.View ArticlePubMedGoogle Scholar
- Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9(8):1760–72.View ArticlePubMedGoogle Scholar
- Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc. 2009;41(10):4352–6.View ArticlePubMedGoogle Scholar
- Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11–20.View ArticlePubMedGoogle Scholar
- Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42–8.View ArticlePubMedGoogle Scholar
- Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90(12):1312–20.View ArticlePubMedGoogle Scholar
- Borg DJ, Weigelt M, Wilhelm C, Gerlach M, Bickle M, Speier S, et al. Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia. 2014;57(3):522–31.View ArticlePubMedGoogle Scholar
- Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med. 2012;2(2):107–11.View ArticleGoogle Scholar
- Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant. 2012;12(9):2373–83.View ArticlePubMedGoogle Scholar
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–86.View ArticlePubMedGoogle Scholar
- Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3(3):199–210.View ArticlePubMedGoogle Scholar
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87.View ArticlePubMedGoogle Scholar
- Feng G, Wood KJ, Bushell A. Interferon-gamma conditioning ex vivo generates CD25+ CD62L+ Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation. 2008;86(4):578–89.View ArticlePubMedGoogle Scholar
- Graca L, Le Moine A, Lin CY, Fairchild PJ, Cobbold SP, Waldmann H. Donor-specific transplantation tolerance: the paradoxical behavior of CD4+ CD25+ T cells. Proc Natl Acad Sci USA. 2004;101(27):10122–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Fan Z, Spencer JA, Lu Y, Pitsillides CM, Singh G, Kim P, et al. In vivo tracking of ‘color-coded’ effector, natural and induced regulatory T cells in the allograft response. Nat Med. 2010;16(6):718–22.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005;201(7):1037–44.PubMed CentralView ArticlePubMedGoogle Scholar
- Cobbold SP, Castejon R, Adams E, Zelenika D, Graca L, Humm S, et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol. 2004;172(10):6003–10.View ArticlePubMedGoogle Scholar
- Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018–31.View ArticlePubMedGoogle Scholar
- Kendal AR, Chen Y, Regateiro FS, Ma J, Adams E, Cobbold SP, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med. 2011;208(10):2043–53.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239–44.PubMed CentralView ArticlePubMedGoogle Scholar
- Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.View ArticlePubMedGoogle Scholar
- Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25+ CD4+ regulatory T cells. Int Immunol. 2004;16(11):1643–56.View ArticlePubMedGoogle Scholar
- Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007;445(7130):931–5.PubMed CentralView ArticlePubMedGoogle Scholar
- Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936–40.View ArticlePubMedGoogle Scholar
- Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation. 2006;81(11):1589–95.View ArticlePubMedGoogle Scholar
- Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol. 2008;20(1–2):55–60.View ArticlePubMedGoogle Scholar
- Kamada N, Calne RY. A surgical experience with five hundred thirty liver transplants in the rat. Surgery. 1983;93(1 Pt 1):64–9.PubMedGoogle Scholar
- Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.View ArticlePubMedGoogle Scholar
- Horoldt BS, Burattin M, Gunson BK, Bramhall SR, Nightingale P, Hubscher SG, et al. Does the Banff rejection activity index predict outcome in patients with early acute cellular rejection following liver transplantation? Liver Transpl. 2006;12(7):1144–51.View ArticlePubMedGoogle Scholar
- Demetris AJBK, Dhillon AP. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658–63.View ArticleGoogle Scholar
- Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445(7129):766–70.View ArticlePubMedGoogle Scholar
- Hoogduijn MJ, Popp FC, Grohnert A, Crop MJ, van Rhijn M, Rowshani AT, et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation. 2010;90(2):124–6.View ArticlePubMedGoogle Scholar
- Eggenhofer E, Steinmann JF, Renner P, Slowik P, Piso P, Geissler EK, et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol. 2011;24(3):157–63.View ArticlePubMedGoogle Scholar
- Min CK, Kim BG, Park G, Cho B, Oh IH. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(10):637–45.View ArticlePubMedGoogle Scholar
- Bian L, Guo ZK, Wang HX, Wang JS, Wang H, Li QF, et al. In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. Vivo. 2009;23(1):21–7.Google Scholar
- Li A, Zhang Q, Jiang J, Yuan G, Feng Y, Hao J, et al. Co-transplantation of bone marrow stromal cells transduced with IL-7 gene enhances immune reconstitution after allogeneic bone marrow transplantation in mice. Gene Ther. 2006;13(15):1178–87.View ArticlePubMedGoogle Scholar
- Kitagawa Y, Ohkura N, Sakaguchi S. Epigenetic control of thymic Treg-cell development. Eur J Immunol. 2015;45(1):11–6.View ArticlePubMedGoogle Scholar
- Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol. 2007;8(3):277–84.View ArticlePubMedGoogle Scholar
- Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007;179(8):5064–70.View ArticlePubMedGoogle Scholar
- Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–47.View ArticlePubMedGoogle Scholar
- Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35(5):1482–90.View ArticlePubMedGoogle Scholar
- Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M, et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+ CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation. 2007;83(6):774–82.View ArticlePubMedGoogle Scholar
- Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18(8):846–57.View ArticlePubMedGoogle Scholar
- Wang H, Qi F, Dai X, Tian W, Liu T, Han H, et al. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol. 2014;31(2):65–74.View ArticlePubMedGoogle Scholar
- Wang L, Han R, Hancock WW. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. Eur J Immunol. 2007;37(10):2983–90.View ArticlePubMedGoogle Scholar
- English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110(2):91–100.View ArticlePubMedGoogle Scholar
- Ghannam S, Pene J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185(1):302–12.View ArticlePubMedGoogle Scholar
- Gur-Wahnon D, Borovsky Z, Beyth S, Liebergall M, Rachmilewitz J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp Hematol. 2007;35(3):426–33.View ArticlePubMedGoogle Scholar
- Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? Immunol Cell Biol. 2013;91(1):12–8.View ArticlePubMedGoogle Scholar
- English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009;156(1):149–60.PubMed CentralView ArticlePubMedGoogle Scholar